Allena Pharmaceuticals, Inc. Free Cash Flow per Share

Free Cash Flow per Share of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow per Share growth rates and interactive chart. Free cash flow per share. Calculated as operating cash flow minus capital expenditures and divided by the weighted average number of shares outstanding. Free cash flow is the cash flow available to all the investors in a company, including common stockholders, preferred shareholders, and lenders. It is usually used in discounted cash flow models to determine a company's intrinsic value.


Highlights and Quick Summary

  • Free Cash Flow per Share for the quarter ending March 31, 2022 was -0.22 (a 45.87% increase compared to previous quarter)
  • Year-over-year quarterly Free Cash Flow per Share increased by 14.74%
  • Annual Free Cash Flow per Share for 2021 was -0.68 (a -21.96% decrease from previous year)
  • Annual Free Cash Flow per Share for 2020 was -0.87 (a -55.44% decrease from previous year)
  • Annual Free Cash Flow per Share for 2019 was -1.95 (a 25.69% increase from previous year)
  • Twelve month Free Cash Flow per Share ending March 31, 2022 was -0.62 (a 11.78% increase compared to previous quarter)
  • Twelve month trailing Free Cash Flow per Share increased by 2.66% year-over-year
Trailing Free Cash Flow per Share for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
-0.62 -0.56 -0.54 -0.6
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow per Share of Allena Pharmaceuticals, Inc.

Most recent Free Cash Flow per Shareof ALNA including historical data for past 10 years.

Interactive Chart of Free Cash Flow per Share of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Free Cash Flow per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -0.22
2021 -0.15 -0.15 -0.2 -0.19 -0.68
2020 -0.2 -0.14 -0.25 -0.35 -0.87
2019 -0.54 -0.39 -0.61 -0.48 -1.95
2018 -0.43 -0.4 -0.39 -0.33 -1.55
2017 -1.51 -2.62 -3.29 -4.73 -4.67
2016 0.0 -13.15 -17.54
2015 0.0 -10.47

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.